Nirmidas Biotech provides innovative solutions to life science and healthcare problems and aims to improve the quality of human life. Nirmidas develops and manufactures breakthrough technologies in biological testing, assays, and imaging, based on a novel red to near-infrared fluorescence enhancing detection platform. They aim to develop personal and portable diagnostic systems for early disease diagnosis and prognosis monitoring, as well as for population-based screening applications. Our products lie at the intersection of life science research, in vitro diagnosis, and digital healthcare.
Nirmidas Biotech, Inc. develops, manufactures, and markets biological testing, assay, and imaging technologies for life science and healthcare applications. It offers bare slides; COOH functionalized slides with PEG cushions; COOH functionalized slides without PEG; NH2 functionalized slides with PEG cushions; NH2 functionalized slides without PEG; and monolayer functionalized slides that are used for fluorescence enhancement, surface enhancement, and fluorescence and Raman enhanced imaging. The company also provides beads for fluorescence enhancement and imaging applications, which include bare beads, COOH functionalized beads, and functionalized beads.
This technology belongs to Hongjie Dai, a professor of Stanford Univercity. And It is confirmed by Dr.Jose Montoya's ToXoSerology Lab. Stanford Univercity is one of the shareholders.
Nirmidas Biotech Series A Equity Financing collected 5 millon dollars, ended on November 30th, 2015. It will help to expand business in North America, Europe and China. Caus Capital in Vancouver sucessfully collected 3 millon dollars for this investment.